Drug intelligence / Profile preview

ERXC102

Development stage: Preclinical
Lead developer: EnduRx Pharmaceuticals
Modality: Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Oral, Intraperitoneal

Overview

ERXC102 is a preclinical-stage therapeutic candidate being developed by EnduRx Pharmaceuticals for the treatment of ovarian cancer and peritoneal carcinomatosis. The drug utilizes EnduRx's proprietary peptide-directed polymeric nanoparticle platform, which is designed to enhance the targeted delivery of chemotherapy agents directly to tumor tissues. By coupling therapeutic payloads to nanoparticles guided by specific peptides, the platform aims to improve tumor-specific accumulation and penetration while minimizing systemic toxicity. This approach is intended to optimize the therapeutic index of anti-cancer agents in the context of peritoneal neoplasms and advanced solid tumors.

Beyond the preview

Go deeper on ERXC102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERXC102.

Explore the full profile